By FDA; Wednesday, October 13, 2010

FDA: Possible increased risk of thigh bone fracture with bisphosphonates

Labeling change adds warning about possible risks of long-term use of osteoporosis drugs

The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk.

To read more visit, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm

The latest

The National Osteoporosis Foundation has named Barbara Hannah Grufferman as its first Bone Health Ambassador. In this newly-established role, Grufferman, a well-known advocate for healthy and positive living, will dedicate her time, talent and energy to raise awareness for osteoporosis and the importance of building strong bones for life.

Thanks to a generous gift from The Samuel J. & Ethel LeFrak Charitable Trust, the National Osteoporosis Foundation met its Generations of Strength fundraising goal one year early. NOF launched the Generations of Strength initiative in September 2011 with the goal of raising $2 million in two years to improve patient care for the most vulnerable – those who have broken bones due to osteoporosis – and to protect future generations from the disease.

The National Osteoporosis Foundation (NOF), the nation’s leading health organization dedicated to preventing osteoporosis and broken bones, has named Claire Gill as its Senior Director of Marketing, Consumer and Corporate Outreach.  Gill brings extensive experience in public relations and marketing communications to this newly-established role.